Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.

Slides:



Advertisements
Similar presentations
Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.
Advertisements

Antiretroviral Drug Resistance
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia
Adriana Weinberg, MD University of Colorado Denver.
Robert Ketcham & Sue Katz Creating a new problem space: Genetic Diversity of Mycobacterium tuberculosis.
HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.
Summary Slide Presentation Principles of HIV drug resistance for clinical management in South Africa Stott K, Michel J, de Oliveira T. Principles of HIV.
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
HIV-1 subtype C now accounts for approximately 50% of the estimated 33 million people living with HIV/AIDS and half of the 1-2 million new infections annually.
Gastroenterology Volume 142, Issue 4, April 2012, Pages 790–795 Tom W. Chu.
HIV-1 evolution in response to immune selection pressures
HIV Genotyping: Sharing Experiences and Protocols Justen Manasa PhD Candidate Africa Centre for Health and Population Studies Virology laboratory based.
Estimating fitness landscapes John Pinney
Homework 2 Part I: Drug Resistance and the Three Great Pandemics.
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
SATuRN HIV-1 Genotyping System Justen Manasa Africa Centre for Health and Population Studies Virology laboratory based at the Nelson R. Mandela School.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
How Does Antiretroviral Therapy Affect HIV Mutation and Vice Versa? Arlin Toro Devin Iimoto Devin Iimoto.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Patterns of selection for or against amino acid change among different CD4 T-cell count progressor groups Michael Pina, Salomon Garcia Journal Club Presentation.
On the protease gene, no major mutation was detected. However, many minor mutations, feature of the non B strains, were present and the most important.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
EVOLUTIONARY ANALYSIS 1. To show the kind of questions evolutionary biologist investigate. 2. Demonstrate how an evolutionary view can inform researchers.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.
Analysis of Recombination in the HIV-1pol Gene Richard Myers Division of Infection and Immunity University College London.
Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.
In vitro activity of candidate microbicides against cell-associated HIV Philippe Selhorst, Katrijn Grupping, Johan Michiels, Kevin Ariën and Guido Vanham.
SC.912.L Mutations 2. Genetic Recombination (sexual reproduction)
Figure 1: Percentage change in the number of people dying from AIDS-related causes between 2005 and 2011 in countries with 100 or more AIDS-related deaths.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Evolution and transmission in HIV Steve Paterson Review; Rambaut 2004 Nature Reviews Genetics 5: ‘The causes and consequences of HIV evolution’
1 Uses of Data from the WHO HIV Drug Resistance Strategy: 1. Monitoring of HIVDR emerging in treated groups in sentinel ART clinics HIV Drug Resistance.
Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,
Meeting the Global Challenge ~ International workshop on antiviral drug resistance.
Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model.
Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.
Viral evolution and adaption
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960
Session 3: Molecular Epidemiology Introduction
8. Causality assessment:
71 ViroLab – A virtual laboratory for decision support in viral diseases treatment ViroLab is sponsored by the European Union (contract number )
Background Results Methods Conclusion
Introduction Results Objectives Methods Conclusion Funding
Utilizing research as an opportunity to strengthen
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
Figure 3 Risk-adapted and response-adapted
Antiretroviral therapy coverage in sub-Saharan Africa,
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:
Drug-resistant human immunodefiency virus
A Web-based Interactive Genome Library for Surveillance, Detection, Characterization and Drug-Resistance Monitoring of Influenza Virus Infection in the.
T. M. Walker, M. Merker, T. A. Kohl, D. W. Crook, S. Niemann, T. E. A
Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.
Next-generation sequencing technology in clinical virology
Evolution and transmission in HIV
Drug Resistance and the Three Great Pandemics
Jennifer Gauvin, Group Head and Director
Stratified Medicine: Will it be the Future of Medicine?
What's New in PAH?.
Illustrative Cluster Detection and Response Strategy
Dolutegravir in PEPFAR
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
Share your thoughts on this presentation with #IAS2019
Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012).

Introduction The diversity of human immunodeficiency virus type 1 (HIV-1) has given rise to multiple subtypes and recombinant strains. The majority of research into antiretroviral agents and drug resistance has been performed on subtype B viruses, yet nonsubtype B strains are responsible for 90% of global infections. Although it seems that combination antiretroviral regimens are effective against all HIV-1 subtypes, there is emerging evidence of subtype differences in drug resistance, relevant to antiretroviral strategies in different parts of the world. Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Summary of main concepts HIV-1 diversity has given rise to numerous subtypes and recombinant forms. New subtyping tools (e.g. Rega HIV-1 Subtyping Tool version 3, SCUEL and COMET) can accurately identify the most important HIV-1 variants. HIV-1 subtype genetic variation can influence the development of drug resistance and the susceptibility to certain antiretroviral drugs. K65R is an example of a clinically relevant mutation that emerges more frequently and more rapidly in subtype C viruses compared to subtype B.. Appreciation of subtype differences is important in the development of new drugs and in the formulation of antiretroviral strategies. Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Figure 1: Recombination profile and phylogenies of recombinant regions One of the new features of Rega Subtyping Tool version 3.0 is that it can perform detailed recombination analyses. The tool detects recombination, identifies the recombinant fragments and creates a phylogenetic tree fragments (Query sequence is at the top of the phylogenies). [Rega HIV Subtyping Tool V3; Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Table 1: Recently described drug resistance mutations between HIV-1 subtypes and CRFs and impact on antiretroviral drug resistance and susceptibility Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Table 2: Virological outcomes with specific antiretroviral drugs across different HIV-1 subtypes (Part I: Clinical trials) Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Table 2: Virological outcomes with specific antiretroviral drugs across different HIV-1 subtypes (Part II: Cohort studies) Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Conclusions There is no compelling evidence that HIV-1 subtype needs be considered in the choice of ART regimens for first-line or second-line therapy, and other considerations of cost, effectiveness, toxicities and tolerability are more important in low-income and middle-income countries. However, recent evidence of subtype differences in drug resistance could potentially impact on antiretroviral strategies. The appreciation of subtype differences is also important to the development of new drugs, treatment strategies, drug sequencing, assessing response to treatment and surveillance for the transmission of resistance. In each of these areas, and in tracking the evolution of the HIV-1 pandemic, differences among subtypes continue to play an important role. Reference: Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012)

Open Access Article Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5): (2012) Corresponding Author: Dr. Tulio de Oliveira